Biotech Values

[Mufaso]

rfj1862 - The phase 3 readout on ARAV's Batiraxcept is imminent. I listened to the Aravive fireside chat and it was very technical with lots of time spent on the drugs MOA and market opportunity. The CEO appeared to be very open and transparent.

Here is the link and it will be available till July 24:

https://ir.aravive.com/events/event-details/william-blairs-innovator-series-transitioning-biotech-breakthroughs-commercial

There is a large short position on this stock which is 6.5 million shares which has increased by 1.4 million shares from the prior month to about 11 % of shares outstanding. Since insiders hold 50% and institutions hold 22%, the short position is 122% of the float!!

As you have said, this stock is either going to rocket in one direction or the other. Any current thoughts on the stock in light of the recent chat or increased short position from you or anyone else? FWIW, I decide to buy a bit more and wait out the P3 results.